55242-55-2

Basic information

• Product Name: PROPENTOFYLLINE
• Synonyms: 1-(5-oxohexyl)-3-methyl-7-propylxanthine;3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl-1h-purine-6-dione;albert-285;hextol;hoe-285;karsivan;HWA 285;3,7-DIHYDRO-3-METHYL-1-(5-OXOHEXYL)-7-PROPYL-1H-PURINE-2,6-DIONE
• CAS NO: 55242-55-2
• Molecular Formula: C₁₅H₂₂N₄O₃
• Molecular Weight: 306.36
• Product Categories: All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 55242-55-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 64-66°C
• Boiling Point: 541.4 °C at 760 mmHg
• Flash Point: 281.2 °C
• Appearance: white/
• Density: 1.25 g/cm³
• Vapor Pressure: 8.71E-12mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: −20°C
• Solubility: H2O: soluble12.4mg/mL
• PKA: 0.58±0.70(Predicted)
• CAS DataBase Reference: PROPENTOFYLLINE(CAS DataBase Reference)
• NIST Chemistry Reference: PROPENTOFYLLINE(55242-55-2)
• EPA Substance Registry System: PROPENTOFYLLINE(55242-55-2)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22
• WGK Germany: 3
• RTECS: UO8438700
• Hazardous Substances Data: 55242-55-2(Hazardous Substances Data)

Usage

Description

Propentofylline is a nootropic indicated for cerebrovascular disorders. Other indications currently under investigation include senile dementia, stroke and hypoxia.

Chemical Properties

Off-White Solid

Originator

Hoechst AG (W.Germany)

Uses

Different sources of media describe the Uses of 55242-55-2 differently. You can refer to the following data:
1. A c-AMP phosphodiesterase inhibitor. A nerve growth factor stimulator. An adenosine transport inhibitor. A non-selective adenosine receptor antagonist. Nootropic.
2. A c-AMP phosphodiesterase inhibitor. A nerve growth factor stimulator. An adenosine transport inhibitor. A non-selective adenosine receptor antagonist. Nootropic

Brand name

Hextol

Biochem/physiol Actions

c-AMP phosphodiesterase inhibitor; nerve growth factor stimulator; adenosine transport inhibitor; non-selective adenosine receptor antagonist.

InChI:InChI=1/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3

Upstream product

• 55242-64-3 3-methyl-7-propyl-xanthine 
• 10226-29-6 6-Bromo-2-hexanone 

Downstream Products

• 56395-62-1 A 720287 

Relevant articles and documents

Combination preparation for use in dementia

The invention relates to a composition which is a pharmaceutical combination preparation comprising a compound which has an acetylcholinesterase-inhibitory action or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level, wherein the combination preparation is suitable for the treatment of dementia. The invention further relates to a process for the production of the combination preparation. The invention additionally relates to a process for treating patients in need of suitable therapy with the combination preparation.

Xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas

The use of xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas (CCT) The use of xanthine derivatives of the formula I STR1 and of their physiologically tolerable salts, in which R1 is oxoalkyl, hydroxyalkyl or alkyl, R2 is hydrogen or alkyl and R3 is hydrogen, alkyl, oxoalkyl or an alkyl having up to 6 carbon atoms, whose carbon chain is interrupted by an oxygen atom, for the production of pharmaceuticals for the treatment of disorders which can occur after cranio-cerebral traumas is described.

Pharmaceutical combination preparations containing cephalosporin and xanthine derivatives and their use

Pharmaceutical combination preparations containing cefotaxime and at least one xanthine derivative are suitable for the treatment of bacterial infectious diseases and for the treatment of septic shock.